| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 09/16/2010 | US20100233192 Manufacturing Method of Activated Lymphocytes for Immunotherapy |
| 09/16/2010 | US20100233191 Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins |
| 09/16/2010 | US20100233190 Targeted polymeric prodrugs containing multifunctional linkers |
| 09/16/2010 | US20100233189 Crystal structure |
| 09/16/2010 | US20100233188 Antibodies and pharamcetical compositions containing same useful for inhibiting activity of metalloproteins |
| 09/16/2010 | US20100233187 Gene products differentially expressed in cancerous cells |
| 09/16/2010 | US20100233186 Novel receptor that binds ctla-8 |
| 09/16/2010 | US20100233185 Caries Risk Test for Predicting and Assessing the Risk of Disease |
| 09/16/2010 | US20100233184 Methods of reducing phosphate absorption |
| 09/16/2010 | US20100233183 Cytotoxic anti-lag-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| 09/16/2010 | US20100233182 Antibodies against Clostridium difficile toxins and uses thereof |
| 09/16/2010 | US20100233181 Antibodies against clostridium difficile toxins and uses thereof |
| 09/16/2010 | US20100233180 Antibodies that bind to an epitope on the huntington's disease protein |
| 09/16/2010 | US20100233179 BAFF, inhibitors thereof and their use in the modulation of B-cell response |
| 09/16/2010 | US20100233178 Use of antibodies for the vaccination against cancer |
| 09/16/2010 | US20100233177 Molecules and methods for modulating proprotein convertase subtilisin/kexin type 9 (pcsk9) |
| 09/16/2010 | US20100233176 Methods and systems for predicting misfolded protein epitopes |
| 09/16/2010 | US20100233175 Antibodies relating to pivkaii and uses thereof |
| 09/16/2010 | US20100233174 Anthrax carbohydrates, synthesis and uses thereof |
| 09/16/2010 | US20100233173 Multispecific epitope binding proteins and uses thereof |
| 09/16/2010 | US20100233172 Methods of inhibiting quiescent tumor proliferation |
| 09/16/2010 | US20100233171 Differential Drug Sensitivity |
| 09/16/2010 | US20100233170 Fully human antibodies against N-Cadherin |
| 09/16/2010 | US20100233169 Methods for treating obesity using fibroblast growth factor-Like polypeptides |
| 09/16/2010 | US20100233168 Rationale for IL-1 Beta targeted therapy in sickle cell disease for ischemia-reperfusion induced complications |
| 09/16/2010 | US20100233167 Chain reaction creating oligomers from repeat units of binding molecules |
| 09/16/2010 | US20100233166 Novel ido inhibitors and methods of use |
| 09/16/2010 | US20100233165 Internalizing human monoclonal antibodies targeting prostate cancer cells in situ |
| 09/16/2010 | US20100233162 LOCAL ADMINISTRATION OF CHICKEN YOLK IMMUNE GLOBULINS (IgY) TO TREAT AND PREVENT FUNGAL INFECTIONS |
| 09/16/2010 | US20100233161 Novel multifunctional compounds for pharmaceutical purposes |
| 09/16/2010 | US20100233160 Monoclonal Anti-Annexin A3 Antibodies for the Detection of Prostate Carcinoma |
| 09/16/2010 | US20100233159 Methods of treating stroke |
| 09/16/2010 | US20100233158 Induction of immune tolerance |
| 09/16/2010 | US20100233157 Human antibodies against human fas and their use |
| 09/16/2010 | US20100233156 Treating Central Nervous System Injury with Beta and Gamma Secretase Inhibitors |
| 09/16/2010 | US20100233155 Humanized anti-ccr2 antibodies and methods of use therefor |
| 09/16/2010 | US20100233154 Targeted binding agents directed to heparanase and uses thereof 463 |
| 09/16/2010 | US20100233153 Novel gene disruptions, compositions and the methods relating thereto |
| 09/16/2010 | US20100233152 Use of HMGB proteins and nucleic acids that code therefor |
| 09/16/2010 | US20100233126 Polypeptide |
| 09/16/2010 | US20100233122 Novel benzimidazole derivatives |
| 09/16/2010 | US20100233121 Method for treating multiple sclerosis |
| 09/16/2010 | US20100233119 Suppression of immune response to factor viii in hemophilia a patients |
| 09/16/2010 | US20100233118 Use of wf10 for treating allergic asthma, allergic rhinitis and atopic dermatitis |
| 09/16/2010 | US20100233117 Adjuvant combination formulations |
| 09/16/2010 | US20100233087 Cyp1b1 nucleic acids and methods of use |
| 09/16/2010 | US20100233084 Method for Delivery Across the Blood Brain Barrier |
| 09/16/2010 | US20100233083 Microparticles comprising a crosslinked polymer |
| 09/16/2010 | US20100233080 Antigen Binding Molecules that Bind EGFR, Vectors Encoding Same, and Uses Thereof |
| 09/16/2010 | US20100233079 Dual Variable Domain Immunoglobulins and Uses Thereof |
| 09/16/2010 | CA2755121A1 Combination therapy with thiocolchicine derivatives |
| 09/16/2010 | CA2755047A1 Treatment methods for autoimmune disorders |
| 09/16/2010 | CA2754961A1 Treatment and diagnostic methods for hypersensitive disorders |
| 09/16/2010 | CA2754938A1 Anti-bcma antibodies |
| 09/16/2010 | CA2754906A1 Antigen presenting cell targeted vaccines |
| 09/16/2010 | CA2754900A1 Humanized pcrv antibody having anti-pseudomonal activity |
| 09/16/2010 | CA2754862A1 Anti-cd40 antibodies and uses thereof |
| 09/16/2010 | CA2754764A1 Antigen presenting cell targeted cancer vaccines |
| 09/16/2010 | CA2754743A1 Antigen presenting cell targeted anti-viral vaccines |
| 09/16/2010 | CA2754603A1 Non-integrating retroviral vector vaccines |
| 09/16/2010 | CA2754591A1 Generation, expression and characterization of the humanized k33n monoclonal antibody |
| 09/16/2010 | CA2754539A1 Antibody molecules having binding specificity for human il-13 |
| 09/16/2010 | CA2753883A1 A pkn3/rhoc macromolecular complex and methods of use therefor |
| 09/16/2010 | CA2751301A1 Optimized early-late promoter combined with repeated vaccination favors cytotoxic t cell response against antigens in replication deficient recombinant virus vaccines |
| 09/15/2010 | EP2228654A2 Diagnosis and prevention of cancer cell invasion |
| 09/15/2010 | EP2228392A1 Monoclonal antibody capable of binding to anexelekto, and use thereof |
| 09/15/2010 | EP2228391A2 Immunoglobulins directed against Nogo |
| 09/15/2010 | EP2228390A1 Therapeutic uses of monoclonal antibodies to the angiotensin-II type-1 receptor |
| 09/15/2010 | EP2228389A2 Antibodies against vascular endothelial growth factor 2 |
| 09/15/2010 | EP2228385A1 Chlamydia trachomatis genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection |
| 09/15/2010 | EP2228384A1 Chlamydia trachomatis genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection |
| 09/15/2010 | EP2228073A1 Pharmaceutical compositions containing monoclonal anti idiotypic anti-ca-125 antibody and aluminium derivatives |
| 09/15/2010 | EP2228072A1 Cancer vaccine composition |
| 09/15/2010 | EP2228059A1 Chemotherapeutic composition for the treatment of cancer |
| 09/15/2010 | EP2227490A2 Monoclonal antibodies and binding fragments thereof directed to the melanocortin-4 receptor and their use in the treatment of cachexia and related conditions and diseases |
| 09/15/2010 | EP2227489A2 Method for the detection of dead and dying cells |
| 09/15/2010 | EP2227486A1 Peptide analogues and conjugates thereof |
| 09/15/2010 | EP2227256A1 Method for treating bone fracture with anti-sclerostin antibodies |
| 09/15/2010 | EP2227255A1 Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods |
| 09/15/2010 | EP2227253A1 Vaccine comprising monocyte or immature myeloid cells(imc) which were loaded with the ligand of natural killer t cell and antigen |
| 09/15/2010 | EP2227252A2 New adjuvant |
| 09/15/2010 | EP2227250A2 Chlamydia antigens |
| 09/15/2010 | EP2227249A1 Improved immunizing composition |
| 09/15/2010 | EP2227248A2 Adjuvanted glucans |
| 09/15/2010 | EP2227243A2 A pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate |
| 09/15/2010 | EP1576179B1 Methods and compositions for inducing apoptosis in cancer cells |
| 09/15/2010 | EP1572976B1 Modulating immune responses |
| 09/15/2010 | EP1543838B1 Feline infectious peritonitis vaccine |
| 09/15/2010 | EP1536837B1 Composition for cytocompatible, injectable, self-gelling chitosan solutions for encapsulating and delivering live cells or biologically active factors |
| 09/15/2010 | EP1450857B1 Broadly cross-reactive neutralizing antibodies against human immunodeficiency virus selected by env-cd4-co-receptor complexes |
| 09/15/2010 | EP1309617B1 Process for the selection of hiv-1 subtype c isolates, selected hiv-1 subtype isolates, their genes and modifications and derivatives thereof |
| 09/15/2010 | EP1154793B1 Use of bioadhesives and adjuvants for the mucosal delivery of antigens |
| 09/15/2010 | EP1026949B1 Outer membrane proteins of ehrlichia chaffeensis |
| 09/15/2010 | CN1951502B Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same |
| 09/15/2010 | CN1616654B Inactivating and purifying method for SARS virus and method for preparing said inactivated virus vaccine and said vaccine |
| 09/15/2010 | CN101835896A Production and use of epitope-tagged hepatitis c virus particle |
| 09/15/2010 | CN101835894A EBI3, DLX5, NPTXl and CDKN3 for target genes of lung cancer therapy and diagnosis |
| 09/15/2010 | CN101835892A CDCA1 peptide and pharmaceutical agent comprising the same |
| 09/15/2010 | CN101835889A TR1 cells, mesenchymal stem cells and uses thereof |
| 09/15/2010 | CN101835796A Vaccine antigen capable of inducing cross-reacting and neutralizing antibody against high-risk-type human papillomavirus |